Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine

Brunetti, P; Muggeo, Michele; Cattin, Luigi; Arcangeli, A.; Pozzilli, Paolo; Provenzano, Vincenzo; Francesconi, Andrea; Calatola, P.; Santeusanio, Fausto

doi:10.1016/j.numecd.2009.05.007

Cited by 14 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another meta-analysis confirmed these results and also indicated less weight gain in patients on first-generation long-acting insulin analogues versus those on NPH insulin RCT [95,97] RCT, OL [79,81] RCT, OL, CO [83] RCT, OL ? Ext [80,82,85] Ext [96] Glulisine TID or RCT, OL [74,88] RCT, OL, CO [75][76][77] [15]. Comparative studies of these insulin analogues are discussed in the following sections, and Fig.…”

Section: Pharmacokinetics Pharmacodynamics Clinical Efficacy and Smentioning

confidence: 99%

Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review

et al. 2020

View full text Add to dashboard Cite

Here, we review insulin management options and strategies in nonpregnant adult patients with type 1 diabetes mellitus (T1DM). Most patients with T1DM should follow a regimen of multiple daily injections of basal/bolus insulin, but those not meeting individual glycemic targets or those with frequent or severe hypoglycemia or pronounced dawn phenomenon should consider continuous subcutaneous insulin infusion. The latter treatment modality could also be an alternative based on patient preferences and availability of reimbursement. Continuous glucose monitoring may improve glycemic control irrespective of treatment regimen. A glycemic target of glycated hemoglobin \ 7% (53 mmol/mol) is appropriate for most nonpregnant adults. Basal insulin analogues with a reduced peak profile and an extended duration of action with lower intraindividual variability relative to neutral protamine Hagedorn insulin are preferred. The clinical advantages of basal analogues compared Enhanced Digital Features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.11310668.

show abstract

Section: Pharmacokinetics Pharmacodynamics Clinical Efficacy and Smentioning

confidence: 99%

Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Overall, 27 studies involving a total of 7452 randomised patients were included in the meta-analysis . In terms of study design, 12 studies were parallel group [15,16,20,25,28,29,31,[33][34][35][36][37] and 15 were crossover studies ( Supplementary Table S1) [17-19, 21-24, 26, 27, 30, 32, 38-41].…”

Section: Literature Search Resultsmentioning

confidence: 99%

“…Data for preprandial BG were only available in studies of patients with T1D [15,16,24,30,36]; in this analysis, which showed low heterogeneity across studies (heterogeneity v 2 = 5.26; P = 0.26; I 2 = 24%, 95% CI 11-54%), there was a non-significant trend favouring RHI (Fig. 1c).…”

Section: Between-group Differences In Preand Postprandial Bgmentioning

confidence: 93%

“…Vignati et al 1997 [30], (n=328)Gallagher et al 2007 [39], (n=18)OVERALL 1.8 (-9.7; 13.3), 0.759 -12.6 (-30.2; 5.0), 0.162 Ciofetta et al 1999 [15], (n=24) Lalli et al 1999 [16], (n=56) Pfützner et al 1996 [24], (n=107) Vignati et al 1997 [30], (n=379) Brunetti et al 2010[36], (n=395) Difference in blood glucose with rapid-acting insulin analogues and regular human insulin (fixed-effects model). Postprandial blood glucose in patients with a type 1 diabetes (mg/dL) or b type 2 diabetes (mg/dL).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes

et al. 2019

View full text Add to dashboard Cite

Introduction: The aim of this meta-analysis was to investigate the impact of rapid-acting insulin analogues (RAIAs) and regular human insulin (RHI) on glycemic control, including long-and short-term glycemic variability as Enhanced Digital Features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.10282829.More data are required to assess the relative effects of RAIAs and RHI on glucose control in patients with type 2 diabetes.

show abstract

“…Over the past 10‐15 years, in particular, the need for intensive treatment strategies in type 1 diabetes has become more widely acknowledged. With the introduction and growing use of rapid‐acting insulin analogs (RAIAs), long‐acting insulin analogs (LAIAs) , and novel technologies (eg, SAP therapy), disease‐management trends and patterns have changed . Studies identified in this review provide evidence that the risk of SH is influenced by insulin type, by new methods of administering insulin (eg, CSII, SAP), and by the insulin administration schedule.…”

Section: Discussionmentioning

confidence: 99%

Incidence of severe hypoglycemia and possible associated factors in pediatric patients with type 1 diabetes mellitus in the real‐life, post‐DCCT setting: a systematic review

Cherubini¹,

Rabbone

Lombardo

et al. 2019

Pediatr Diabetes

View full text Add to dashboard Cite

Background/Objective In 1993, the Diabetes Control and Complications Trial (DCCT) found that intensive antihyperglycemic therapy was effective in the primary and secondary prevention of microvascular complications in patients with type 1 diabetes (T1D) but was associated with a 3‐fold greater rate of severe hypoglycemia (SH) than conventional therapy. The aim of this analysis was to determine whether, in the real‐world setting, the incidence of SH in pediatric patients with T1D has changed since 1993. Methods A systematic literature search of PubMed for prospective or retrospective observational studies (≥250 participants) on SH epidemiology or related topics in pediatric patients with T1D, published between October 1993 and June 2016, identified 35 articles (involving >55 000 participants). SH incidence data were analyzed in approximate 5‐year blocks: 1993‐2000, 2001‐2005, 2006‐2010, and 2011‐2016. Information on factors that might influence the incidence of SH was also collected. Results A trend for a marked reduction in the incidence of SH in the post‐DCCT setting (from 62.0 per 100 patient‐years to 1.21‐30 per 100 patient‐years) was apparent. Factors that could have influenced this temporal trend in SH incidence included the increased use of new types of, and methods of administering, insulin, in particular rapid‐acting insulin analogs and continuous subcutaneous insulin infusion. Conclusions SH in pediatric patients with T1D has declined in incidence since the DCCT but remains a common problem. The optimal use of new insulin therapies/regimens/technologies, improved education, and dedicated specialized management teams are needed to help reduce the risk of SH in this population.

show abstract

Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine

Cited by 14 publications

References 12 publications

Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review

Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review

Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes

Incidence of severe hypoglycemia and possible associated factors in pediatric patients with type 1 diabetes mellitus in the real‐life, post‐DCCT setting: a systematic review

Contact Info

Product

Resources

About